Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B
The German biotech will partner with Genentech, part of the Roche Group, to develop targeted…
29/08/2018 - 2 minutes
Immuno-oncology
Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe
Update: Following on from earlier approvals in the US, the European Commission announced it has given…
28/08/2018 - 4 minutes
Update: Yet Another ADC Company Makes Bank, This Time in Series B
Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M),…
29/06/2018 - 3 minutes
German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn
Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR…
14/05/2018 - 2 minutes
Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV
TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation…
08/05/2018 - 2 minutes
Novartis and Gilead’s CAR-T Therapies Now Compete for the Same Cancer Patients
The FDA has approved the use of Novartis' CAR-T therapy Kymriah in adult patients with…
02/05/2018 - 2 minutes
The First CAR-T Therapy Is Not Living Up to Commercial Expectations
Novartis' Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in…
23/04/2018 - 3 minutes
French CAR-T Developer Raises $164M Despite a Challenging Road
Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in…
11/04/2018 - 3 minutes
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
09/04/2018 - 4 minutes
Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech
OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has…
05/04/2018 - 2 minutes
The Most Important Battle in Gene Editing: CRISPR versus TALEN
Despite all the hype, CRISPR is still not in the clinic as a standalone therapy…
13/03/2018 - 6 minutes
Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?
Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that…
01/03/2018 - 3 minutes
